Connect your AI

Rhythm Pharmaceuticals, Inc. RYTM Royalties

Other financials

Income statement

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept rytm:RoyaltiesCurrent.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s royalties.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s royalties?: Rhythm Pharmaceuticals, Inc. (RYTM) reported royalties of $3.01M in Q1 2026.